The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The newly certified kits are designed for early detection and large-scale screening programs
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Subscribe To Our Newsletter & Stay Updated
